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Abstract
Background: Recent evidence indicates that insulin resistance in skeletal muscle may be related to reduce mitochondrial
number and oxidation capacity. However, it is not known whether increasing mitochondrial number and function improves
insulin resistance. In the present study, we investigated the effects of a combination of nutrients on insulin resistance and
mitochondrial biogenesis/function in skeletal muscle of type 2 diabetic Goto–Kakizaki rats.
Methodology/Principal Findings: We demonstrated that defect of glucose and lipid metabolism is associated with low
mitochondrial content and reduced mitochondrial enzyme activity in skeletal muscle of the diabetic Goto-Kakizaki rats. The
treatment of combination of R-a-lipoic acid, acetyl-L-carnitine, nicotinamide, and biotin effectively improved glucose
tolerance, decreased the basal insulin secretion and the level of circulating free fatty acid (FFA), and prevented the reduction
of mitochondrial biogenesis in skeletal muscle. The nutrients treatment also significantly increased mRNA levels of genes
involved in lipid metabolism, including peroxisome proliferator–activated receptor-a (Ppara), peroxisome proliferator–
activated receptor-d (Ppard), and carnitine palmitoyl transferase-1 (Mcpt-1) and activity of mitochondrial complex I and II in
skeletal muscle. All of these effects of mitochondrial nutrients are comparable to that of the antidiabetic drug, pioglitazone.
In addition, the treatment with nutrients, unlike pioglitazone, did not cause body weight gain.
Conclusions/Significance: These data suggest that a combination of mitochondrial targeting nutrients may improve
skeletal mitochondrial dysfunction and exert hypoglycemic effects, without causing weight gain.
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Introduction
Increasing evidence suggests that mitochondrial dysfunction due
to oxidative damage is a major contributor to aging, degenerative
diseases such as cancer, and metabolic syndrome, such as obesity
and type 2 diabetes [1,2,3]. Skeletal muscle insulin resistance may
play an important role in the pathogenesis of the metabolic
syndrome and 2 type diabetes [4]. Recent studies reported insulin
resistance is associated with impaired skeletal muscle oxidation
capacity and reduced mitochondrial number and function [5,6].
Therefore, protecting mitochondria from oxidative damage to
improve mitochondrial function in skeletal muscle seems a possible
strategy to prevent and treat diseases associated with mitochon-
drial dysfunction [7,8,9,10]. For example, rosiglitazone improves
the suppression of adipose mitochondrial biogenesis in db/db and
high fat diet-fed mice [11]. Pioglitazone reduces hyperglycemia,
hyperlipidemia, and hyperinsulinemia in male fatty rats [12],
improves mitochondrial function and stimulates mitochondrial
biogenesis in human adipocyte/tissue in vitro [13,14] or human
neuron-like cells [15]. Metformin delays the manifestation of
diabetes and vascular dysfunction and reduces mitochondrial
oxidative stress in Goto-Kakizaki (GK) rats [16]. However, the use
of any pharmacological therapy for type 2 diabetes, such as
thiazolidinedione, insulin, metformin, and other oral hypoglyce-
mic agents or combination therapy with or without insulin appears
to be associated with an increased risk of heart failure and body
weight gain [17]. Therefore, effective treatments without apparent
side effects are greatly needed for preventing and treating diabetes
and other metabolic syndromes.
We have defined a group of mitochondrial targeting antiox-
idants/metabolites as mitochondrial nutrients [8,9,18], i.e.,
nutrients which improve mitochondrial function and protect
mitochondria from oxidative damage, including those that can
1) inhibit or prevent oxidant production in mitochondria; 2)
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3) repair mitochondrial damage and enhance antioxidant defenses
by stimulating mitochondrial biogenesis and inducing phase-2
enzymes; and 4) act as cofactors/substrates to protect mitochon-
drial enzymes and/or stimulate enzyme activity. One good
example of mitochondrial nutrients is R-a-lipoic acid (LA)
[9,19,20,21].
More recently, we have examined the effect of LA and acetyl-L-
carnitine (ALC), as well as their combination, on mitochondrial
biogenesis in 3T3-L1 adipocyte. We found that treatment with a
combination of LA and ALC significantly improved mitochondrial
function and increased mitochondrial biogenesis related transcrip-
tion factors while the treatments with only LA and ALC alone at
the same concentrations showed little effect [22]. From these
results, we have concluded that the combination of mitochondrial
targeting nutrients may complementarily promote mitochondrial
synthesis and adipocyte metabolism and possibly, like thiazolidi-
nedione drugs, prevent and treat insulin resistance in type 2
diabetes. In the present study, we investigated the effects of a
combination of LA and ALC, with two other mitochondrial
nutrients, nicotinamide and biotin, on improving glucose toler-
ance, insulin release, fatty acid metabolism, and mitochondrial
biogenesis and function in the spontaneous diabetic GK rats.
Results
Metabolic characteristics of GK rats
The metabolic characteristics of GK rats are summarized in
Table 1. After the 12-week administration, there was no difference
in body weight between the untreated and the nutrients-treated
GK rats, however, the body weight in the pioglitazone-treated
group was significantly higher than that of other groups. The
pioglitazone-induced gain of body weight is consistent with a
previous report [23]. The pioglitazone treatment tended to
increase food intake (measured for individual rats in g/kg/24 h)
and significantly reduced the levels of triglyceride and total
cholesterol in blood. The nutrients-treatment did not affect fasting
glucose and triglyceride levels, but significantly reduced fasting
plasma insulin (p,0.01 vs. GK) and slightly decreased total
cholesterol level in GK rats.
Effects on glucose tolerance and plasma FFA
We first examined whether the mitochondrial nutrient treatments
could improve the glucose tolerance because hyperglycemia is the
defining characteristic of type 2 diabetes and improvement of glucose
tolerance is one of the most critical criteria for evaluating the
effectiveness of hypoglycemic drugs. Fig 1A illustrates changes in the
blood glucose levels during OGTT in GK and Wistar rats.
Hyperglycemic responses in GK rats to OGTT were significantly
greater than those in Wistar rats. In the diabetic GK rats treated with
nutriments for 12 week, the levels of glucose obtained 60, 120 and
180 min after glucose intake were significantly lower than that in the
untreated GK diabetic rats (24.461.0 mmol/l vs. 27.861.0 mmol/l,
p,0.05; 21.160.9 mmol/l vs. 24.760.9 mmol/l, p,0.01 and
12.961.3 mmol/l vs. 15.061.5 mmol/l, p,0.01, respectively).
The blood glucose level at 60 min in the pioglitazone-treated diabetic
rats was also significantly lower than the corresponding control
diabetic value (22.661.6 mmol/l vs.27.861.0 mmol/l, p,0.05)
(Figure 1A).
Chronic elevation in plasma FFA levels is commonly associated
with impaired insulin-mediated glucose uptake in skeletal muscles
and often coexists with obesity and type 2 diabetes. The higher
FFA may cause peripheral insulin resistance by interfering with the
access of insulin to skeletal muscle or the insulin signaling resulting
in reduced glucose transport into muscle [24]. Therefore, lowering
FFA has been postulated to be a potential therapeutic target for
type 2 diabetes. In our results, we have found that the plasma FFA
in the GK diabetic rats was significantly higher than those in the
non-diabetic Wistar rats before treatments. After 12 week
treatment, the plasma FAA was significantly decreased in all
groups with drugs. The increases in plasma FFA in the untreated
GK diabetic rats were still significantly higher than those in the
non-diabetic Wistar rats (Fig 1B).
Effects on mitochondrial DNA and protein in soleus
muscle
D-loop is known as the major site of transcription initiation on
both the heavy and light strands of mtDNA. In Fig 2A, the ratio of
mtDNA D-loop/nuclear DNA 18S rRNA in GK rats was
significantly lower than that in Wistar rats (p,0.01vs.wistar
control). The pioglitazone-treated diabetic rats was significantly
higher than the untreated GK diabetic rats (p,0.05 vs. control). In
the diabetic rats treated with nutriments for 12 week, the ratio of
mt D-loop/18S rRNA was significantly higher than the untreated
GK diabetic rats (p,0.05 vs. GK control).
If there is an increased mitochondrial DNA content, there
should be a concomitant increase in viable mitochondria and
mitochondrial components, including electron chain transport
complex enzymes. We examined the effects of mitochondrial
nutrients on the expression of complex I and II and found that the
expression of complex I and complex II (Fig 2B) in GK rats were
significantly lower than Wistar rats (8264.2% p,0.05 vs. Wistar
control; 74.567.0% p,0.05 vs. Wistar control; respectively). In
the diabetic GK rats treated with nutriments, the expression of
complex I and complex II were increased significantly compared
with that in the untreated GK rats (152618%, p,0.05 vs. GK
control; 12166.7%, p,0.05 vs. GK control; respectively). The
expression of complex I, but not complex II, in the pioglitazone-
treated GK rats was also significantly higher than the GK control
rats (144612.6%. p,0.01vs.GK control).
Effects on mitochondrial complex activities
The improvement of the expression of the mitochondrial
complex enzymes suggests there should be a consequent
improvement of the complex enzyme activity in the GK rats.
Our measurement showed that the activity of mitochondrial
complex I and II (Fig 3) were significantly lower in GK rats than in
Wister rats (80.566.3%, p,0.05 vs. control; 89.961.9%, p,0.01
vs. control; respectively) and the administration of mitochondrial
Table 1. Morphometric and plasma variables in GK rats with
different treatments.
GK
GK with
nutrients
GK with
pioglitazone
Body weight (g) 326.5626.0 329.2619.8 419.3621.6 **
Food intake (g/kg/d) 81.566.5 78.1.4611.1 84.8612.4
Fasting plasma glucose (mmol/l) 6.060.15 5.660.16 5.860.23
Fasting plasma insulin (ng/ml) 1.0660.14 0.6060.08* 0.9960.07
Triglycerides (mmol/l) 1.8360.04 1.8660.23 0.8360.04**
Total cholesterol (mmol/l) 3.0660.06 2.8760.15 2.5960.04 *
Values are mean6SEM of 12 animals in each group.
*p,0.05 vs. GK control;
**p,0.01 vs. GK control.
doi:10.1371/journal.pone.0002328.t001
Mt Nutrients on GK Rats
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the activity of complex I (10465.0%, p,0.05 vs. GK control;
11065.4%, p,0.05 vs. GK control, respectively) and the activity
of complex II (114.267.1%, p,0.05 vs. GK control;
114.667.4%, p,0.05 vs. GK control, respectively).
Effects on expression of PPARGC1A, Nrf1 and Tfam
Peroxisome proliferator activator protein-c co-activator-1a
(PPARGC1A) is a transcription coactivator that promotes
mitochondrial biogenesis and mitochondrial fatty acid oxidation.
Increasing evidence suggests that PPARGC1A is involved in the
pathogenesis of type 2 diabetes by playing a pivotal role in the
control of genetic pathways that result in homeostatic glucose
utilization in liver and muscle, beta cell insulin secretion and
mitochondrial biogenesis [25,26]. Rosiglitazone was shown to
restore PPARGC1A expression in obese patients with type 2
diabetes mellitus [27]. In our study, no difference in PPARGC1A
expression was found between the Wistar and the untreated GK
rats, however, both the treatment with pioglitazone (210645%,
p,0.01 vs. GK control) and mitochondrial nutriments
(224625%, p,0.01 vs. GK control) significantly increased the
expression of PPARGC1A (Fig 4A).
Figure 1. Effects of mitochondrial nutriments on OGTT and plasma free fatty acid (FFA). A: OGTT was carried out at the end of 12 weeks
of nutrient administration. All rats fasted overnight before OGTT. Blood was taken from the retrobulbar vein at 0, 30, 60, 120 and 180 min after the
oral glucose administration (5 g/kg body weight). Plasma glucose concentration was determined by the glucose oxidase method. Data are
means6S.E. of 12 observations in each group. * p,0.05, **p,0.01 vs. the respective values in the GK control group. B: Plasma free fatty acid was
measured in groups at beginning or after nutrient administration for 12 weeks. Serum levels of free fatty acids in different groups after overnight
fasting. Data are means6S.E. of 12 animals in each group. **p,0.01 vs. the respective values in the Wistar control group. ##p,0.01 vs. the
respective values in the GK control group.
doi:10.1371/journal.pone.0002328.g001
Mt Nutrients on GK Rats
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mitochondrial transcription factor A (Tfam) are involved in
regulating expression of nuclear genes encoding major mitochon-
drial proteins that regulate mtDNA transcription and replication
[9,26]. We could not find difference in the expression of Nrf1
mRNA between the Wistar and the untreated GK rats while the
pioglitazone treatment resulted in a trend towards an increase and
the mitochondrial nutriment administration significantly increased
the mRNA expression of Nrf1 (334674.1, p,0.01vs.GK control)
(Fig 4B). Levels of Tfam mRNA were found to be significantly
lower in the GK rats than in the Wister rats (72.665.7%, p,0.01
vs. Wistar control). After the 12 week treatment, the expression of
Figure 2. Effect of mitochondrial nutriments on mitochondrial DNA and protein in soleus muscle. A: Total DNA was isolated from soleus
muscle. The mtDNA contents were determined by real-time PCR. The DNA contents of mtDNA and nuclear 18S rRNA gene (18S rDNA) were calculated
from the standard curve and the relative ratios of mtDNA contents against nuclear 18S rRNA gene were determined in each group. Results are
expressed as percentage of Wistar control. Data are mean+SEM (n=5). **P,0.01 vs. Wistar control; # p,0.05 vs. GK control. B: Protein (10 mg) was
solubilized in SDS sample buffer and analyzed by western blotting with antibodies against tubulin, mitochondrial electron transport complex I and
complex II. The quantitative analyses of the bands by densitometry are shown. Results are presented as percentage of Wistar control. *p,0.05 vs.
Wistar control; #P,0.05, ##p,0.01 vs. GK control.
doi:10.1371/journal.pone.0002328.g002
Mt Nutrients on GK Rats
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(113.3617.5%, p,0.05 vs. GK control); and in the pioglitazone-
treated group (97.465.0%, p,0.01 vs. GK control).
Effects on expression of Ppara, Ppard and Mcpt-1
Ppara and Ppard, which are ligand-activated transcription
factors, are critical to fat metabolism. Ppara mediates the
hypotriglyceridemic effect of fibrates by inducing high rates of
mitochondrial peroxisome b-oxidation in liver, kidney, heart and
muscle, and by decreasing the plasma concentration of triacylgly-
cerol-rich lipoproteins [28]. Ppard is mainly expressed in brown
adipose tissue and muscle, and specifically induces the expression
of genes required for fatty acid oxidation and energy dissipation
which lead to the improvement of lipid profiles and the reduction
of adiposity [29]. Increasing the level of Ppard in white adipose
tissues has been suggested as a potential strategy to treat obesity
[30]. As shown in Fig 5, levels of Ppara and Ppard mRNA were
significantly lower in GK rats than that in Wister rats (49.662.2%,
p,0.01 vs. Wistar control; and 54.368.2%, p,0.05 vs. Wistar
control, respectively). Administration of mitochondrial nutriments
to the GK rats significantly increased the expression of Ppara
(93615.8%, p,0.05 vs. GK control) and Ppard (108621%,
p,0.05 vs. GK control) in soleus muscle. The treatments with
pioglitazone only significantly increased the expression of Ppara
mRNA (90619.7%, p,0.05 vs. GK control; respectively), but not
Ppard mRNA.
Muscle-type CPT-1 (Mcpt-1) is a protein involved in fatty acid
metabolism and the expression is regulated by PPARs, such as
Ppara in cardiomyocytes [31]. We have found that the level of
Mcpt1 mRNA was significantly lower in GK rats than in Wister
rats (2762.6%, p,0.01) (Fig 5). Administration of the mitochon-
drial nutriments to the GK rats significantly increased the levels of
Mcpt-1 (97618.4%, p,0.05 vs. GK control) in soleus muscle.
Discussion
A recent study indicated that mitochondrial dysfunction is
present in the prediabetic state [32], suggesting that mitochondrial
dysfunction may play a role in the development to 2 type diabetes
[3]. The GK rat is a model of non-obese, spontaneous type II
diabetes. The pathogenesis of diabetes in the GK rat involves an
impaired insulin secretion, insulin resistance, an abnormal glucose
metabolism as well as an impaired ontogenetic development of
pancreatic islet cells [33,34] and mitochondrial dysfunction in the
liver [35] and heart [36]. In the present study, we observed that
defect of glucose and lipid metabolism is associated with low
mitochondrial content and reduced mitochondrial enzyme activity
in skeletal muscle of the diabetic Goto-Kakizaki rats. We have
demonstrated that a combination of 4 mitochondrial nutrients,
comparable to the anti-diabetic drug pioglitazone, ameliorated the
symptoms of diabetes including beta-cell dysfunction, enhanced
mitochondrial biogenesis, improved mitochondrial function and
fatty acid and glucose metabolism in diabetic G-K rats. In
addition, the pioglitazone caused gain of body weight, a known
clinical drawback of thiazolidinedione for treatment of type
2diabetic patients [23]. On contrary, the nutrient treatment did
not cause any significant change of body weight, suggesting there is
an advantage of nutrients over the anti-diabetic drugs.
The combination contains LA, ALC, biotin and niacin. First,
LA has been shown to mitigate insulin resistance in GK rats [37],
and it has also been shown that improvement of insulin sensitivity
is mediated by activation of AMPK and reduced triglyceride
accumulation in skeletal muscle [38].
Second, ALC is the acetyl derivative of L-carnitine which plays
an important role in lipid metabolism, acting as an obligatory
cofactor for beta-oxidation of fatty acids by facilitating the
transport of long-chain fatty acids across the mitochondrial
membrane as acylcarnitine esters. Both L-carnitine and ALC are
shown to be effective in improving insulin-mediated glucose
disposal either in healthy subjects or in type 2 diabetic patients
with two possible mechanisms: regulating acetyl and acyl cellular
trafficking for correctly meeting energy demand and controlling
the synthesis of key glycolytic and gluconeogenic enzymes [39,40].
Third, biotin-dependent carboxylases play important role in
mitochondrial function because four of the five biotin-dependent
carboxylases are in the mitochondria. A high intake of biotin
may exert effects on beta cells, liver and skeletal muscle, that
favor good glucose tolerance [41]. In addition, it was shown that
LA could reduce the activities of biotin-dependent carboxylases,
such as pyruvate carboxylase and b-methylcrotonyl-CoA car-
boxylase, in rat liver while biotin co-treatment with LA could
normalize these carboxylase activities [42]. Though the mild
decreases in carboxylase activities caused by LA would
presumably not cause pathology, it is always essential to keep
homeostasis and avoid side-effects by a simple co-administration
with biotin.
Figure 3. Effect of mitochondrial nutriments on complex I and II enzyme activity in soleus muscle. After 12 week treatment,
mitochondria were isolated from soles and the activities of mitochondrial Complex I and Complex II were assayed spectrometrically using the
conventional assays. Results are presented as percentage of Wistar control. Data are means6SEM of 12 animals in each group. *p,0.05, **p,0.01 vs.
Wistar control; #p,0.05 vs. GK control.
doi:10.1371/journal.pone.0002328.g003
Mt Nutrients on GK Rats
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diseases for improvement of disturbed lipid and lipoprotein
metabolism. It is still the most efficacious drug in terms of its
ability to increase HDL cholesterol content accompanied by a
decrease in all atherogenic lipoproteins as well as fatty acids and
triglycerides. Niacin was shown to be an antilipolytic agent
because it, similar to the adenosine receptor agonist phenyliso-
propyladenosine, lowers plasma glucose, plasma FFA, hepatic
glucose production, and enhances insulin-stimulated glucose
uptake in streptozotocin-induced diabetic rats [43]. There are
studies on niacin against the loss of beta cell function in type 1
diabetes [44,45]. Nicotinamide injection could prevent beta cell
Figure 4. Effect of mitochondrial nutriments on expression of PPARGC1A, Nrf1 and Tfam. A: Western blot analysis in adipocytes of
PPARGC1A. Quantitative values were tabulated with the ratio of densities of PPARGC1A: tubulin. Values are mean6SE of 12 animals in each
group.*p,0.05, p,0.01 vs. Wistar control; # p,0.05, ##p,0.01 vs. GK control. B: Total RNA was isolated from soleus muscle. mRNA of Nrf1 and
Tfam were analyzed by means of quantitative RT-PCR with gene-specific oligonucleotide probes in muscle. The cycle number at which the various
transcripts were detectable was compared to that of nuclear18S rRNA as an internal control, and expressed as arbitrary units versus values in Wistar
control taken 100. All values are mean6SEM of 12 animals in each group.*p,0.05, ** p,0.01 vs. Wistar control; #p,0.05, ##p,0.01 vs. GK control.
doi:10.1371/journal.pone.0002328.g004
Mt Nutrients on GK Rats
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loss, and triglyceride accumulation in obese Zucker diabetic fatty
rats [46]. Nicotinamide was shown to be effective agent for
prevention and treatment of insulin-dependent diabetes mellitus
(IDDM) in prediabetic and early stage IDDM because nicotin-
amide treatments (intramuscularly or orally) normalized antioxi-
dant enzyme system activity and the levels of lipid peroxidation
products, and prevented the occurrence of streptozotocin-induced
diabetes mellitus in rats [47,48]. The main reason for us to include
this B vitamin is mainly to use it as a source of the NADH and
NADPH coenzymes required for mitochondria. NAD (P) H acts as
a donor of hydrogen anion in a variety of enzymatic processes,
such as the reduction of GSSG to GSH. Increased NAD(P)H may
help the reduction of the exogenously administered oxidized form
LA , which needs to be NAD(P)H-dependently reduced in
mitochondria or cytosol [49]. In addition, Kirsch and De Groot
[50] have proposed that NAD(P)H may also act as directly
operating antioxidant, which limit the action of freely diffusing
radicals by scavenging the attacking, oxidizing radical and
reducing oxidized bio-molecules.. Of course, nicotinamide may
also improve pancreatic islet dysfunction, which is an important
feature of GK pathogenesis [33,34].
We have recently examined the effect of LA and ALC as well as
their combination, on mitochondrial biogenesis in 3T3-L1
adipocyte. We found that treatments with the combination of
LA and ALC at concentrations of 0.1, 1, and 10 mM for 24 hrs
significantly increased the number of viable mitochondria,
expression of mitochondrial DNA, mitochondrial complexes,
oxygen consumption, and fatty acid oxidation in 3T3L1 adipocyte.
These changes were accompanied with an increase in the mRNA
expression of Pparc, Ppara, and Cpt-1, and the expression of several
transcription factors involved in mitochondrial biogenesis, Pparg-
c1a,Tfam, and Nrf1 and Nrf2. In contrast, the treatments with only
LA or ALC alone at the same concentrations showed little effect
on mitochondrial function and biogenesis [22]. From these results,
we have concluded that combination of mitochondrial targeting
nutrients/compounds may complementarily promote mitochon-
drial synthesis and adipocyte metabolism and possibly prevent and
treat insulin resistance in type 2 diabetes.
No study has been carried out on the effect of these nutrients on
mitochondrial biogenesis in diabetic animals. Based on our
intriguing results of the combination of LA and ALC on
mitochondrial biogenesis in adipocytes, the main purpose of the
present study is to see whether the in vitro effect of LA and ALC
on mitochondrial function and biogenesis could be replicated in
vivo in an animal model. As shown in our results, the treatment
with the combination of the mitochondrial nutrients stimulated
mitochondrial biogenesis through the activation of the Ppargc1a
pathway, similar to that in 3T3L1 adipocyte. It might be
important to perform a study with the individual nutrients on
mitochondrial biogenesis in the future; however, from the results
we obtained in this in vivo study, we could presume that
mitochondrial biogenesis may be mainly induced by the
combination of LA and ALC. Biotin may play its physiological
role as a prosthetic group in the biotin-dependent carboxylases to
compete with LA to keep the homeostasis of mitochondrial
carboxylases [42]. Nicotinamide may synergize the effect by
providing NAD(P)H for a more reducing environment and
enhancing mitochondrial antioxidant defense, thus, improves
mitochondrial function leading to better glucose tolerance and
maintenance of effective beta cell function.
Although we have termed these nutrients mitochondrial
targeting agents and focused on their effects on mitochondria, it
should be borne in mind that the four nutrients used are also
essential for non-mitochondrial cell functions as well. For example,
although lipoic acid is a mitochondrial co-factor and mainly
located in mitochondria, it is also available to and influences many
activities in other parts of the cell when supplied exogenously.
Therefore, there is a possibility that the outcomes are mediated via
other cellular organelles and the interactions between mitochon-
dria and other organelles, such as endoplasmic reticulum. Future
studies on the multiple functions of these nutrients, such as the
effects on endoplasmic reticulum and the interactions with
mitochondria are warranted.
We have also tested the effect of much higher doses of these
nutrients (10 fold) and found that the higher dose, unlike the lower
dose, did not show significant effects in most of the parameters
examined. The reason for the loss of the effect of higher doses is
unknown but we propose that the nutrients may have a bell-shape
curve of dose-dependent effect as most nutrients and drugs. The
higher dose may fall on the right side of the bell-shape curve. The
loss of the effect might be due to a compromise between the effect
Figure 5. Effect of mitochondrial nutriments on expression of Ppara, Ppard and Mcpt-1. Total RNA was isolated from soleus muscle. Ppara,
Ppard and Mcpt-1 mRNA were analyzed by means of quantitative RT-PCR with gene-specific oligonucleotide probes in muscle. The cycle number at
which the various transcripts were detectable was compared to that of nuclear 18S rRNA as an internal control, and expressed as arbitrary units
versus values in Wistar control taken 100. All values are mean6SEM of 12 animals in each group. *p,0.05, ** p,0.01 vs. Wistar control; #p,0.05,
##p,0.01 vs. GK control.
doi:10.1371/journal.pone.0002328.g005
Mt Nutrients on GK Rats
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of the high dose suggest these nutrients are safe even at 10 fold
doses of their effective doses.
In conclusion, a treatment with a combination of 4 mitochon-
drial nutrients in spontaneous diabetic GK rats, as effectively as
the anti-diabetic drug pioglitazone, improved glucose tolerance,
insulin release, fat acid metabolism, and mitochondrial function
through a stimulation of Ppargc1a regulated mitochondrial
biogenesis pathway. In addition, the treatment with nutrients is
better than with pioglitazone because the nutrient treatment,
unlike pioglitazone, did not cause body weight increase. These
results suggest that a combination of mitochondria-targeting
nutrients may have clinical application for preventing and treating
metabolic syndromes, such as diabetes.
Materials and Methods
Animals
Four-week-old male diabetic GK rats together with age-
matched male non-diabetic Wistar rats were purchased from
SLAC Laboratory Animal Co. Ltd (Shanghai, China). All animals
were housed at 2362uC under 12-h light and dark cycles, and
allowed access to food and water ad libitum. The experiments
were performed in accordance with the Guidelines for Animal
Experiments of the Institute for Nutritional Sciences, Chinese
Academy of Sciences.
Material
Anti-tubulin from Sigma (St. Louis, MO, USA); anti-
PPARGC1A from Santa Cruz (Heidelberg, Germany); anti-
OxPhos Complex I (NADH ubiquinol oxidoreductase 39-kDA
subunit 1:2000), anti-OxPhos Complex II (succinate-ubiquinone
oxidoreductase 70-kDA subunit 1:2000) from Invitrogen (Carls-
bad, USA); Reverse Transcription System kit from Promega
(Manheim, Germany); HotStarTaq from Takara (Otsu, Shiga,
Japan); Nrf1, Ppara, Ppard, Mcpt-1, D-loop and 18S rRNA
primers were synthesized by Bioasia Biotech (Shanghai, China),
and ALC (hydrochloride salt) from Sigma Tau (Pomezia, Italy).
Biotin and nicotinamide were from Boya Biotech (Shanghai,
China), R-a-lipoic acid (tris salt) was a gift from Dr. K. Wessel,
Viatris, Germany. Pioglitazone was a gift from Taian Pharma-
ceutical. Co., Ltd (Shandong, China). TRIzol and other reagents
were from Invitrogen (Carlsbad, USA).
Experimental protocol
Four groups (n=12 in each group) of rats were used: two
control groups: Wistar and GK, and two GK experimental groups
with treatments: a pioglitazone group received pioglitazone
10 mg/kg/day by gavage and a nutriment group received a
combination of R-LA 50 mg/kg/day, ALC 100 mg/kg/day,
biotin 0.1 mg/kg/day and nicotinamide 15 mg/kg/day by
gavage. The control groups were received same gavage volume,
but saline alone, as administered to the experimental groups. The
treatments were started at 6-weeks of age, and continued for 3
months. At approximately 18 weeks of age, animals were
anesthetized with an intraperitoneal injection of sodium pento-
barbital (60 mg/kg) and sacrificed for obtaining soleus muscle
tissue.
Oral glucose and insulin tolerance test
An oral glucose tolerance test (OGTT, 5 g/kg body weight) was
performed after starting nutriment administration following the
previous GK rat study [51]. All rats fasted overnight before
OGTT. Blood was taken from the retrobulbar vein at 0, 30, 60,
120 and 180 min after the oral glucose administration. Plasma
glucose concentrations were determined by the glucose oxidase
method.
Insulin assay
Plasma insulin levels were determined by Rat Insulin-specific
RIA kit (Linco Research, Inc., St. Charles, MO) [52].
Plasma free fatty acid (FFA) measurement
Standard solutions of several saturated and unsaturated fatty
acids of varying chain length were prepared in chloroform;
concentrations were in the range of 10–100 mmol/l. Four-milliliter
portions of the various solutions were placed in 15-ml. stoppered
tubes; 2.0 ml of the copper reagent added; and the tubes shaken
thoroughly for 2 min. After allowing the layers to separate, the
upper, cooper-rich aqueous layer was removed with a fine Pasteur
pipette, leaving no traces of the aqueous layer on the surface of the
chloroform layer containing the copper soap of the acid. This
organic layer must not be contaminated by traces of the copper-
containing aqueous solution. Exactly 3.0 ml of the chloroform
layer was then transferred to a spectrophotometer cuvette of 1-cm
1ight path, and 0.5 ml of the sodium diethyl dithiocarbamate color
reagent added. The contents were mixed by rinsing back and forth
from a pipette. The absorbance at 440 nM was measured; a
sample of chloroform which had been passed through the whole
procedure was used as a reagent blank. The results obtained with
this series of fatty acid solutions of known concentration were used
to prepare a standard calibration curve, from which the
concentration of an unknown can be determined [53,54].
Isolation of skeletal muscle mitochondria
The soleus muscle, which is composed predominantly of type I
muscle fibers rich in mitochondria, was removed from each leg. A
first portion was frozen in liquid N2 and used for total RNA and
protein extraction. A second portion was used immediately for
mitochondrial isolation. Soleus muscles were trimmed off fat and
connective tissue, chopped finely with a pair of scissors, and used
for mitochondrial isolation according to the method of Birch-
Machin et al [55]. Each aliquot was rinsed in ice-cold medium A
(120 mmol/l NaCl, 20 mmol/l HEPES, 2 mmol/l MgCl2,
1 mmol/l EGTA, and 5 g/l bovine serum albumin; pH 7.4) to
remove any residual blood. The disrupted muscle was made up to
20 volumes with respect to the original wet weight of tissue with
medium A and homogenized with a hand-held borosilicate glass
homogenizer. The homogenate was centrifuged at 6006g for
10 min at 4uC. The pellet obtained after centrifugation was
resuspended in 8 volumes of medium A and centrifuged (6006g,
4uC, and 10 min). The 2 supernatant fluids were combined and
were subsequently recentrifuged at 170006g for 10 min at 4uC.
The pellet containing the mitochondria was resuspended in 10
volumes of medium A and then centrifuged at 70006g for 10 min
at 4uC. The pellet obtained after the last centrifugation was
resuspended in 10 volumes of medium B (300 mmol/l sucrose,
2 mmol/l HEPES, 0.1 mmol/l EGTA; pH 7.4) and recentrifuged
(35006g, 10 min, 4uC). The resulting pellet, which contained
soleus muscle mitochondria, was suspended in a small volume of
medium B and was stored at 270uC until analyzed.
RNA isolation and reverse transcription PCR
Total RNA was isolated from ,30 mg of tissue using the single-
step TRI reagent and 1 ug of RNA was reverse transcribed into
cDNA. In brief, the isolated RNA was dissolved in sterile water
and 2.5 mmol/l Mg
2+, 1 mmol/l dNTPs, 0.5 mg oligodT15,2 5U
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of 20 ml. The sample was incubated at 25uC (10 min), 42uC
(60 min), and 99uC (5 min). cDNA was diluted in DNase-free
water (1:25) before quantification by real-time PCR. The primers
for quantization of mRNA by real-time qPCR for Nrf1, Tfam,
Ppara, Ppard, Mcpt-1, and 18S rRNA were listed as below:
Nrf1: Forward: 59-TTACAGGGCGGTGAAATGAC-39,
Reverse: 59- GTTAAGGGCCATGGTGACAG-39;
Tfam: Forward: 59- CCCTGGAAGCTTTCAGATACG-39,
Reverse: 59- AATTGCAGCCATGTGGAGG-39;
Ppara: Forward: 59- TCACACAATGCAATCCGTTT-39,
Reverse: 59-GGCCTTGACCTTGTTCATGT-39;
Ppard: Forward: 59- GCAGATGGGCTGTGATGG-39,
Reverse: 59-ACTGACACTTGTTGCGGTTC -39;
Mcpt-1: Forward: 59-CATGGTGAACAGCAACTATTACG-39,
Reverse: 59-CATCTGGTAGGAGCACATGG-39;
18S rRNA: Forward: 59-CATTCGAACGTCTGCCCTATC-39,
Revese: 59-CCTGCTGCCTTCCTTGGA-39;
Quantitative PCR was performed in Mx3000P Real-Time PCR
system (Stratagene). Each quantitative PCR was performed in
triplicate. The rat 18S rRNA gene served as the endogenous
reference gene. The evaluation of relative differences of PCR
product among the treatment groups was carried out using the
DDCT method. The reciprocal of 2CT (used CT as an exponent
for the base 2) for each target gene was normalized by that for 18S
rRNA, followed by the comparison with the relative value in
control cells. Final results were presented as percentage of control.
Immunoblot analysis of PPARGC1A, complex I and
complex II
For protein blots, approximately 100 mg muscle was homog-
enized in an ice-cold solubilization buffer containing 65 mmol/l
Tris (pH 7.4), 150 mmol/l NaCl, 5 mmol/l EDTA, 1% (v/v)
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 10% glycerol, 1 mg/ml aprotinin, 1 mg/ml leupeptin,
10 mmol/l sodium fluoride, 1 mmol/l Na3VO4, and 1 mmol/l
phenylmethylsulfonylfluoride. Protein concentration was deter-
mined using the Bio-Rad DC protein assay. The soluble lysates
(10 mg per lane) were subjected to 10% SDS-PAGE; proteins were
then transferred to nitrocellulose membranes and blocked with 5%
non-fat milk/TBST for 1 h at room temperature. Membranes
were incubated with primary antibodies directed against
PPARGC1A (1:1000), tubulin (1:5000), complex I (1:2000), and
complex II (1:2000), in 5% milk/TBST at 4uC overnight. After
washing membranes with TBST three times, membranes were
incubated with horseradish peroxidase-conjugated antibody for
1 h at room temperature. Western blots were developed using
ECL (Roche Manheim, Germany) and quantified by scanning
densitometry.
Total DNA isolation and real-time PCR
Total DNA was extracted using the QIAamp. DNA Mini kit,
and quantitative (Q) PCR was performed using mitochondrial
DNA and genomic NA-specific primers. The rat 18S rRNA gene
served as the endogenous reference gene. Melting curves were
obtained to ensure specific amplification. The standard curve
method was used for relative quantification. Final results are
expressed as N-fold differences in mitochondrial D-loop expression
relative to the 18S rRNA gene [22].
Assays for activities of mitochondrial complex I and
complex II
Mitochondria were isolated by differential centrifugation of the
tissue homogenates. NADH-CoQ oxidoreductase (Complex I) and
succinate-CoQ oxidoreductase (complex II) were assayed spectro-
metrically using the conventional assays with minor modifications
[56,57]. NADH–CoQ oxidoreductase (complex I) activity was
assayed by monitoring the reduction of 2,6-dichloroindophenol
indophenol (DCPIP) at 600 nm upon addition of assay buffer (10X
buffer containing 0.5 mol/l Tris–HCl, pH 8.0, 1% BSA,
10 mmol/l antimycin A, 2 mmol/l NaN3, 0.5 mmol/l coenzyme
Q1). Final concentration of mitochondria protein was 25 mg/ml.
Reaction was started by adding 200 mmol/l NADH and scanned
at 600 nm for 2 min. Rotenone (3 mmol/l) was added into the
reaction system as blank control. Briefly, complex II was assayed in
the assay buffer (10Xbuffer contain 0.5 mol/l phosphate buffer,
pH 7.8, 1% BSA, 10 mmol/l antimycin A, 2 mmol/l NaN3,
0.5 mmol/l coenzyme Q1) with mitochondria (final concentration
25 mg/ml). The reaction was started with 10 mM succinate and
scanned at 600 nm for 2 min at 30uC.
Statistics
All values are expressed as means6SEM. Significances of
differences among groups and within groups were evaluated using
repeated measures ANOVA and the paired Student’s t test,
respectively. A p value of less than 0.05 was considered statistically
significant.
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